Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
S412384-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $75.90 | |
S412384-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $139.90 | |
S412384-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $305.90 | |
S412384-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $549.90 | |
S412384-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $799.90 |
JAK3 Selective Inhibitors
Synonyms | 2-(2-Chloro-6-fluorophenyl)-5-(4-(morpholine-4-carbonyl)phenylamino)oxazole-4-carboxamide | SAR20347 | SAR 20347 | 2-(2-Chloro-6-fluorophenyl)-5-[[4-(4-morpholinylcarbonyl)phenyl]amino]-4-oxazolecarboxamide |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | SAR-20347 is a potent inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling. |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of Janus kinase 1;Inhibitor of Janus kinase 2;Inhibitor of Janus kinase 3;Inhibitor of tyrosine kinase 2 |
Product Description | Information SAR-20347 is a potent inhibitor ofTYK2,JAK1,JAK2andJAK3with IC50 of 0.6 nM, 23 nM, 26 nM and 41 nM, respectively. SAR-20347 inhibits TYK2- and JAK1-mediatedIL-12andIFN-αsignaling. Targets IL-12 ; IFN-α ; TYK2 (Cell-free assay); JAK1 (Cell-free assay); JAK2 (Cell-free assay) 32707,; 0.6 nM; 23 nM; 26 nM |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 2-(2-chloro-6-fluorophenyl)-5-[4-(morpholine-4-carbonyl)anilino]-1,3-oxazole-4-carboxamide |
---|---|
INCHI | InChI=1S/C21H18ClFN4O4/c22-14-2-1-3-15(23)16(14)19-26-17(18(24)28)20(31-19)25-13-6-4-12(5-7-13)21(29)27-8-10-30-11-9-27/h1-7,25H,8-11H2,(H2,24,28) |
InChi Key | HEDPDFHTQKEORT-UHFFFAOYSA-N |
Canonical SMILES | C1COCCN1C(=O)C2=CC=C(C=C2)NC3=C(N=C(O3)C4=C(C=CC=C4Cl)F)C(=O)N |
Isomeric SMILES | C1COCCN1C(=O)C2=CC=C(C=C2)NC3=C(N=C(O3)C4=C(C=CC=C4Cl)F)C(=O)N |
PubChem CID | 71727668 |
Molecular Weight | 444.84 |
PubChem CID | 71727668 |
---|---|
CAS Registry No. | 1450881-55-6 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2417277 | Certificate of Analysis | Mar 29, 2024 | S412384 |
G2417284 | Certificate of Analysis | Mar 29, 2024 | S412384 |
G2417287 | Certificate of Analysis | Mar 29, 2024 | S412384 |
G2417310 | Certificate of Analysis | Mar 29, 2024 | S412384 |
G2417321 | Certificate of Analysis | Mar 29, 2024 | S412384 |
G2417346 | Certificate of Analysis | Mar 29, 2024 | S412384 |
G2417360 | Certificate of Analysis | Mar 29, 2024 | S412384 |
G2417361 | Certificate of Analysis | Mar 29, 2024 | S412384 |
Solubility | Solubility (25°C) In vitro DMSO: 89 mg/mL (200.07 mM); Water: Insoluble; Ethanol: Insoluble; |
---|
Starting at $69.90
Starting at $150.90
Starting at $107.90
1. Works MG, Yin F, Yin CC, Yiu Y, Shew K, Tran TT, Dunlap N, Lam J, Mitchell T, Reader J et al.. (2014) Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.. J Immunol, 193 (7): (3278-87). [PMID:25156366] [10.1021/op500134e] |